Previous Article | Next Article 
Infection and Immunity, June 2001, p. 3628-3634, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3628-3634.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Biological Activity of a C-Terminal Fragment of
Pasteurella multocida Toxin
Christian
Busch,
Joachim
Orth,
Nabil
Djouder, and
Klaus
Aktories*
Institut für Experimentelle und
Klinische Pharmakologie und Toxikologie der
Albert-Ludwigs-Universität Freiburg, D-79104 Freiburg, Germany
Received 28 November 2000/Returned for modification 19 January
2001/Accepted 7 March 2001
 |
ABSTRACT |
The protein toxin of Pasteurella multocida PMT is a
potent mitogen and activator of phospholipase C
. In this study
different toxin fragments were investigated. A C-terminal fragment
encompassing amino acids 581 through 1285 (PMT581C) was constructed,
which was inactive toward intact embryonic bovine lung (EBL) cells
after addition to culture medium but caused reorganization of the actin cytoskeleton and rounding up of cells when introduced into the cells by
electroporation. As the holotoxin, the toxin fragment PMT581C induced
an increase in total inositol phosphate levels after introduction into
the cell by electroporation. A C-terminal fragment shorter than PMT581C
as well as N-terminal fragments were inactive. Exchange of
cysteine-1165 for serine in the holotoxin resulted in a complete loss
of the ability to increase inositol phosphate levels. Correspondingly,
the mutated toxin fragment PMT581C.C1165S was inactive after cell
introduction by electroporation, suggesting an essential role of
Cys-1165 in the biological activity of the toxin.
 |
INTRODUCTION |
The bacterium Pasteurella
multocida is the causative agent of atrophic rhinitis in animals
and causes wound infections in humans. PMT is sufficient to induce all
major symptoms of atrophic rhinitis in animals (3, 10).
PMT appears to act on the
-subunit of the Gq,11 family
of heterotrimeric G proteins (25), which stimulates
phosphatidylinositol hydrolysis, resulting in an increase in inositol
phosphate and diacylglycerol levels (21) and a
mobilization of intracellular calcium pools. Moreover, the toxin is a
potent mitogen for several cell types (4, 13, 16) and
stimulates anchorage-independent DNA synthesis and growth in soft agar
in Rat1 fibroblasts (9). The mitogenic effect of PMT on
HEK293 cells seems to be caused by stimulation of the mitogen-activated protein kinase pathway via Gq,11-dependent transactivation
of the epidermal growth factor receptor (20). In Swiss 3T3
cells, this mitogenic effect of PMT is transient and is followed by a blockade of the cell cycle progression (23).
In cultured cells, PMT induces pronounced cytoskeletal changes.
Treatment of Swiss 3T3 fibroblasts results in stress fiber formation
and focal adhesion assembly (4, 11), which has been
proposed to be caused by an activation of the small GTP-binding protein
Rho (11). Similarly, stress fiber formation and an
increased permeability of endothelial monolayers of human umbilical
vein endothelial cells induced by PMT are dependent on the activation of the Rho-signaling pathway (5). A different cytopathic
effect of PMT is observed in Vero and embryonic bovine lung (EBL)
cells, which is characterized by rounding up of cells (15,
17).
PMT consists of 1,285 amino acid residues and the primary structure of
the N terminus of the toxin has 24 and 27% identity at the amino acid
level to the N terminus of the cytotoxic necrotizing factors CNF1 and
CNF2, respectively, of Escherichia coli. CNF1 and CNF2 are
deamidases acting on Rho proteins (7, 18). The catalytic
domain of CNF1 is localized to the C-terminal part of the protein
(12, 19), whereas the N-terminal part harbors the
receptor-binding domain (6, 12). In keeping with this domain structure of CNF1, an amino acid in the C-terminal part of PMT
was proposed to be important for biological activity of the toxin
(22). In a recent study, however, the biological activity of PMT was localized to the N-terminal part of the holotoxin
(24). To clarify this discrepancy, we studied the effects
of various fragments of PMT on EBL cells in more detail. Here we report
that a C-terminal fragment of PMT elicits the same effects in EBL cells as the holotoxin, suggesting that this part of the toxin is responsible for its biological effects.
 |
MATERIALS AND METHODS |
Abbreviations used in this paper.
CNF1 and CNF2, E. coli cytotoxic necrotizing factors 1 and 2; EBL cells, embryonic
bovine lung cells; GST, glutathione S-transferase; PMT,
P. multocida toxin; MEM, modified Eagle's medium; FCS,
fetal calf serum; TRITC, tetramethylrhodamine-5-isothiocyanate.
Materials.
[3H]inositol was obtained from
DuPont NEN (Dreieich, Germany). PCR primers were from MWG Biotech
(Ebersberg, Germany). All other reagents were of analytical grade and
were purchased from commercial sources.
PCR amplification.
P. multocida serovar D, strain
P824 (kindly donated by D. Schimmel, Jena, Germany), was used as a
source of chromosomal DNA. PMT was amplified with a PCR System 2400 from Perkin Elmer (Überlingen, Germany), using the primer
pairs PMTsen and PMTanti (5'-AGATCTATGAAAACAAAACATTTTTTTAACTC-3' and 5'-GGATCCTAGTGCTCTTGTTAAGCGAGG-3'). The reaction
was carried out with 4 U of Taq polymerase (Roche, Mannheim,
Germany), 600 nM each primer, and 300 ng of chromosomal DNA for 30 cycles (denaturation, 94°C for 10 s; annealing, 48°C for
30 s; elongation, 68°C for 6 min) in a total volume of 100 µl.
The amplified DNA fragment was cloned into pCR2.1 (Invitrogen BV,
Groningen, The Netherlands). After mobilization with BamHI,
the fragment was cloned into the expression vector pGEX-2T.
Cloning of truncated PMT fragments.
PMT in pGEX-2T was used
for subcloning the truncated fragments PMT483 and PMT1130, consisting
of amino acid residues 1 through 483 and 1 through 1130, respectively.
For the generation of PMT1130.pGEX-2T, the PMT.pGEX-2T construct was
digested with EcoRI and the truncated vector construct
was purified and religated. PMT483.pGEX-2T was obtained by
digesting PMT.pGEX-2T with HindIII-BamHI. The
truncated vector construct fragment was isolated, treated with the
Klenow fragment of DNA polymerase I to generate blunt ends, and religated.
The C-terminal fragments PMT581C and PMT701C were obtained by PCR
amplification using PMT.pGEX-2T as a template. Amplicons were cloned
into pGEX-2T. The primers used were PMT581Csen
(5'-AGATCTAGTCCTTTCCGTATTGGATTA-3') and PMTanti for
PMT581C.pGEX-2T and PMT701Csen
(5'-GCGGGATCCGAAATGGCTGGAAAAACCAG-3') and PMTanti for
PMT701C.pGEX2T.
Site-directed mutagenesis of PMT and PMT581C.
The QuikChange
kit (Stratagene, Amsterdam, The Netherlands) was used for mutating one
nucleotide in PMT.pGEX-2T and PMT581C.pGEX-2T, resulting in
PMT.Cys1165Ser and PMT581C.Cys1165Ser, respectively. Procedures were
carried out as specified by the manufacturer, using the primer pair
PMT.C1165Ssen and PMT.C1165Santi
(5'-GAAGCTGGCTCTTCTGATTCAGTAAGC-3' and
5'-GCTTACTGAATCAGAAGAGCCAGCTTC-3').
Sequencing.
Sequencing of PMT.pGEX-2T and all its truncated
derivatives was done with the ABI PRISM Dye Terminator cycle-sequencing
ready-reaction kit (Perkin Elmer, Überlingen, Germany) to
check for correct cloning and mutations due to PCR amplification.
Sequencing was performed with overlapping DNA fragments.
Cell culture.
Embryonic bovine lung cells (17)
were grown as monolayers in MEM containing streptomycin (100 µg/ml),
penicillin (100 U/ml), and 15% FCS in a humidified atmosphere of 5%
CO2 and 95% air. Cells were subcultured every 2 to 3 days.
Expression of recombinant proteins.
Recombinant PMT and
toxin fragments were expressed in E. coli strain TG1 and
purified as GST fusion proteins as specified by the manufacturer. GST
fusion proteins from the E. coli vector pGEX2T were isolated
by affinity chromatography with glutathione-Sepharose (Amersham
Pharmacia Biotech, Freiburg, Germany) followed by proteolytic cleavage
using 3.25 U of thrombin/mg of recombinant GST fusion protein. Thrombin
was removed by incubation with benzamidine-Sepharose (Amersham
Pharmacia Biotech).
Analysis of total inositol phosphates.
EBL cells were grown
in 24-well plates for 2 to 3 days. Then cultures were labeled with 2 µCi of [2-3H]inositol per ml in serum-free medium
(MEM-Waymouth medium [1:1]) overnight. Subsequently, PMT or PMT
fragments at the indicated concentrations and LiCl (20 mM) were added
at the indicated time points, and the cells were incubated for the
indicated times. Thereafter, the medium was replaced by 750 µl of
ice-cold 10 mM formic acid (pH 3). After 30 min, the extract was
neutralized with 3 ml of 5 mM NH3 (pH 8 to 9). Total
inositol phosphates were analyzed by anion-exchange chromatography.
Samples were loaded onto columns containing 1 ml of AG1-X8 resin (200 to 400 mesh; Bio-Rad, Munich, Germany) preequilibrated with 5 mM
NH3 (pH 8 to 9). After the columns were washed with 4 ml of
40 mM ammonium formate, total inositol phosphates were eluted with 4 ml
of 2 M ammonium formate. The eluate was counted in 4 ml of Ultima Gold cocktail (Packard Bioscience e.v., Groningen, The Netherlands).
Electroporation of EBL cells.
Confluent EBL cells, which had
or had not been prelabeled with 2 µCi of [2-3H]inositol
per ml, were trypsinized as usual. A 400-µl volume of cell suspension
in MEM plus 15% FCS containing approximately 5 × 105
cells and the indicated proteins or substances was placed in a
0.4-cm-gap-width electroporation cuvette (Bio-Rad). Electroporation was
performed using a Gene Pulser transfection apparatus (Bio-Rad), which
was set at a capacitance of 950 µF and a voltage of 200 V at room
temperature. After electroporation, 100-µl aliquots of the cell
suspension were transferred to 24-well plastic dishes containing 500 µl of prewarmed MEM plus 15% FCS and incubated for the indicated
times at 37°C under 5% CO2. Then photographs were
obtained or the amount of total inositol phosphates was determined, respectively.
Actin cytoskeleton staining.
Cells were electroporated in
the presence of the indicated agents as described above. They were then
seeded on coverslips and incubated for 6 h at 37°C under 5%
CO2. After removal of the medium, the cells were fixed for
30 min with a solution containing 3.7% formaldehyde and 1% Triton
X-100 and incubated with TRITC-conjugated phalloidin (4 µg/ml) for 45 min (each step was preceded by three washes in phosphate-buffered
saline). After the inverted coverslips were mounted in gelatine on
glass slides, the cells were examined and photographed.
 |
RESULTS |
Recently, contradictory data have been reported on the
localization of the domain carrying the biological activity in PMT. While the N terminus of the toxin was described to elicit effects dependent on Gq in Xenopus oocytes
(24), the replacement of a cysteine residue at the C
terminus (Cys1165) by serine was reported to result in a complete loss
of toxic activity in vivo (22).
To clarify this issue, we studied the effects of the holotoxin and
different toxin fragments in EBL cells. To this end, the PMT gene was
cloned in the expression vector pGEX2T and various toxin fragments were
constructed (Fig. 1). After expression in E. coli and purification by affinity chromatography, GST
fusion proteins were cleaved by thrombin to obtain the recombinant
proteins. A sodium dodecyl sulfate-polyacrylamide gel electrophoresis
analysis of the toxin and the fragments is shown in Fig.
2. Next we tested the recombinant PMT for
its ability to induce morphological effects in EBL cells. As described
previously (17), the holotoxin provoked dramatic changes
in cell morphology and actin cytoskeleton organization in this cell
type. In particular, shrinking of the cell body and formation of
lamellipodia-like protrusions were observed. Moreover, PMT led to a
reorganization of the actin cytoskeleton. While control cells exhibited
thick actin stress fibers (Fig. 3A),
PMT-treated cells showed a dense network of often
parallel-orientated, delicate fibers (Fig. 3B). During the process of
rounding, these fibers disappeared and completely rounded cells showed
very little actin structures (data not shown). These effects were
clearly different from those elicited by the rho-inactivating fusion
toxin Clostridium botulinum C3 transferase (1)
(Fig. 3H) and the E. coli cytotoxic necrotizing factor 1 (CNF1) (Fig. 3G), which activates rho proteins. On CNF1 treatment,
actin was translocated to the cell-cell contacts, associated with an
enlargement of the cell body. On the other hand, inactivation of Rho by
the C3 fusion toxin resulted in a total loss of actin structures and a
shrinking of the cells.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the PMT fragments used in
this study. The regions homologous to E. coli CNF1 and CNF2
are marked in gray.
|
|

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 2.
Purified recombinant PMT, toxin fragments, and mutants.
The recombinant toxin and fragments were constructed as GST fusion
proteins, expressed in E. coli, purified by affinity
chromatography, and cleaved by treatment with thrombin. PMT (lane 1),
PMT.Cys1165Ser (lane 2), PMT1130 (lane 3), PMT483 (lane 4), PMT581C
(lane 5), PMT581C.Cys1165Ser (lane 6), and PMT701C (lane 7) are shown.
Protein was loaded at a rate of 3 µg for lanes 1 and 3 to 7 and 1 µg on lane 2.
|
|

View larger version (109K):
[in this window]
[in a new window]
|
FIG. 3.
Actin staining of EBL cells. (A and B) Effect of
PMT on EBL cells after addition to the medium. Cells were incubated
with PMT (1 µg/ml) (A) or control buffer (B) for 6 h at 37°C under
5% CO2 in serum-free medium. (C to H) Effect of PMT and
toxin fragments on EBL cells after electroporation. EBL cells were
electroporated in the presence of control buffer (C), 1 µg of PMT per
ml (D), 1 µg of PMT581C per ml (E), or 100 µg of PMT1130 per ml (F)
as described in Materials and Methods. The cells were then seeded on
coverslips and incubated for 6 h at 37°C under 5%
CO2. After fixation of the cells, cellular actin was
stained with TRITC-phalloidin. Other cells were incubated in the
presence of 1 µg of CNF1 per ml (G) or the fusion toxin of the
N-terminal part of the C. botulinum C2I toxin component
fused to the C3 transferase (100 ng/ml) together with the activated
form of C2II (200 ng/ml) (H). After 4 h, the cells were fixed and
stained by TRITC-phalloidin.
|
|
To test the PMT fragments for activity on cell morphology, we added
them to the culture medium of EBL cells. However, none of the proteins
was cytopathic towards EBL cells (data not shown).
To circumvent the uptake process necessary for intracellular toxin
action, we introduced the toxin and the fragments into EBL cells by
electroporation. When suspended EBL cells were electroporated in the
presence of control buffer, they attached to the culture dish within 90 min, resulting in a dense monolayer like that formed by untreated cells
90 min after seeding (Fig. 3C and 4A).
The differences in morphology in Fig. 3A and C are explained by
different cultivation times after seeding (24 h for the cells in Fig.
3A, and 90 min for those in Fig. 3C). To test electroporation as a method of introducing cytotoxic proteins into cells, we studied the
effects of the enzymatically active fragment of Clostridium difficile toxin B (B546), which is incapable of cell binding and entry. EBL cells electroporated in the presence of the toxin B fragment
failed to attach to the matrix and exhibited a rounded morphology
typical of intoxication with toxin B (data not shown). Therefore, we
concluded that electroporation allows the introduction of protein
toxins into EBL cells.

View larger version (156K):
[in this window]
[in a new window]
|
FIG. 4.
Morphological effects of recombinant PMT, toxin
fragments, and mutants on EBL cells after electroporation.
Electroporation was performed as described in Materials and Methods.
Cells were electroporated in the presence of control buffer or
recombinant proteins. They were then seeded in 3-cm-diameter dishes and
incubated for 4 h at 37°C under 5% CO2. Photographs
were taken. (A) Control buffer; (B) PMT (200 ng/ml); (C) PMT.Cys1165Ser
(2 µg/m); (D) PMT1130 (2 µg/ml); (E) PMT483 (2 µg/ml); (F)
PMT581C (200 ng/ml).
|
|
When electroporated in the presence of PMT, EBL cells reattached to the
matrix, as did control cells. Within 3 h, however, these cells
adopted the same morphology as that observed after application of PMT
to intact cells; e.g., the cells rounded up and showed a redistribution
of the actin cytoskeleton (Fig. 3D and 4B). On introduction of the
N-terminal fragments PMT483 (Fig. 4E) and PMT1130 (Fig. 3F and 4D) into
the cells, no morphological changes were observed. However, the
C-terminal fragment PMT581C, encompassing amino acids 581 through 1285, elicited the same morphological effects as did the holotoxin when
introduced by electroporation (Fig. 4F). Moreover, this fragment led to
a redistribution of actin structures identical to that of the holotoxin
(Fig. 3E), while a C-terminal fragment shorter than PMT581C (PMT701C)
had no effect on cell morphology and the actin cytoskeleton (data not shown).
To further characterize the toxin fragments, we investigated their
effects on inositol phosphate accumulation in EBL cells using
[3H]inositol-labeled monolayers. As found for other cell
types (13, 14, 21), addition of the holotoxin to the
culture medium led to an increase in the amount of total inositol
phosphates, indicating an increased activity of phospholipase C (Fig.
5A). Addition of the toxin fragments to
the culture medium had no effect, even when they were added at a more
than 500-fold higher concentration than required for an effect of the
holotoxin (Fig. 5A). Next, we tested the effects of the different
fragments on inositol phosphate accumulation after electroporation.
Again, the N-terminal fragments had no effect. However, the C-terminal
fragment PMT581C provoked an increase in inositol phosphate levels to
the same extent as that observed with the holotoxin. However, PMT701C
was inactive (Fig. 5B).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Effects of PMT, toxin fragments, and mutants on inositol
phosphate accumulation in EBL cells. (A) PMT, fragments, or mutants
were applied to cultured EBL cells in the presence of 20 mM LiCl. After
90 min, the total amount of inositol phosphates in the cells was
measured. Data are given as fold induction of buffer control plus 20 mM
LiCl (means and standard error; n = 3). Proteins were
applied at 2 µg/ml or 200 ng/ml (PMT), 20 µg/ml (PMT701C), or 100 µg/ml (PMT581C, PMT581C.Cys1165Ser, PMT483, and PMT1130). (B) PMT,
fragments, or mutants were introduced into EBL cells by electroporation
in the presence of 20 mM LiCl. After 90 min, the total amount of
inositol phosphates in the cells was measured as described in Materials
and Methods. Data are given as fold induction of buffer control plus 20 mM LiCl (means and standard error; n = 3). Proteins
were applied at a concentration of 5 µg/ml (PMT and PMT581C), 20 µg/ml (PMT701C), or 100 µg/ml (PMT581C.Cys1165Ser, PMT483, and
PMT1130).
|
|
The concentration-effect relationship of the active fragment PMT581C on
inositol phosphate accumulation was compared with that of the
holotoxin. As shown in Fig. 6, similar
concentration-effect curves were obtained for the two proteins. Next,
the time dependence of the effect of PMT581C on inositol phosphate
accumulation was compared with the stimulation of inositol phosphate
production induced by the stable GTP analogue GTP
S. As can be seen
in Fig. 7, the two agents caused similar
profiles and the same maximal extent of inositol phosphate accumulation
over the times given.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 6.
Concentration-effect dependency of PMT versus PMT581C
after electroporation of EBL cells. Electroporation of EBL cells was
performed as described in Materials and Methods in the presence of the
indicated concentrations of PMT or PMT581C, respectively. Then the
cells were seeded in 24-well plates and incubated for 2 h at
37°C. After addition of 20 mM LiCl, the cells were further incubated
for 90 min. Subsequently, the total amount of inositol phosphates was
determined as described in Materials and Methods. Data are given as
means and standard errors (n = 3).
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 7.
Time dependency of inositol phosphate accumulation after
introduction of GTP S or PMT581C into EBL cells. EBL cells were
electroporated in the presence of 1 mM GTP S or 2.5 µg of PMT581C
per ml. Then they were incubated at 37°C under 5% CO2 in
medium containing 15% FCS and 20 mM LiCl. At the indicated time
points, the medium with the nonattached cells was removed and the cells
were centrifuged at 800 rpm for 3 min and resuspended in formic acid
(10 mM). The suspension was added to the attached cells and incubated
for 30 min at 4°C. Subsequently, the total amount of inositol
phosphates was determined as described in Materials and Methods. Data
are given as means and standard errors (n = 3).
|
|
Recently it was shown that the mutant Cys1165Ser of PMT is nontoxic to
cells (22). Although the study did not permit
clarification the functional role of this cysteine residue, it was
suggested that Cys1165 is essential for the biological activity of PMT
(22). We confirmed that the Cys1165Ser mutant of PMT had
no cytopathic effects on intact cells (data not shown). To clarify the
role of the Cys1165, we studied the effects of the cysteine exchange with serine in the holotoxin PMT and in the PMT581C fragment after electroporation. As shown in Fig. 5B, the Cys1165Ser mutant of PMT581C
failed to increase the amount of total inositol phosphates and did not
influence cell morphology after electroporation (data not shown). The
same was found for the holotoxin mutant (Fig. 4C).
 |
DISCUSSION |
EBL cells have been used to assess the activity of PMT. These
cells show a typical cytopathic morphology on treatment with PMT
(17). In this study we investigated the effects of PMT and toxin fragments on EBL cells. Consistent with a previous study (24), we observed that none of the toxin fragments studied
induced a cytopathic effect when applied to the cell culture medium of intact cells. However, a C-terminal fragment encompassing amino acids
581 through 1285 (PMT581C) provoked the same morphological changes and
redistribution of the actin cytoskeleton as did the holotoxin when
introduced into cells by electroporation (Fig. 4). Moreover, this
fragment caused an increase in total inositol phosphate levels similar
to that observed with the holotoxin (Fig. 5B) and was as efficient as
the parent toxin (Fig. 6). PMT581C increased the total inositol
phosphate levels to the same extent as GTP
S did (Fig. 7). The stable
GTP analogue presumably stimulates inositol phosphate production by
direct activation of the Gq protein, which is an activator of
phospholipase C (2). In some experiments we observed a lag
phase in the onset of inositol accumulation induced by the toxin
fragment. However, because measurements at early time points are
unreliable (e.g., duration of leakage of the cells after
electroporation), we are unable to decide whether an activating step is
necessary for the action of PMT581C. Nevertheless, the data indicate
that regions of PMT which are responsible for the intracellular
biological activity in EBL cells are included in PMT581C. A fragment
encompassing amino acids 701 through 1285 (PMT701C) exhibited no
activity in our system. Therefore, at least a part of the region
covered by amino acids 581 through 700 seems to be important for
the biological activity and/or stability of the active fragment.
Moreover, even high concentrations of PMT581C had no effect when
applied to the cell culture medium. These data indicate that the
fragment is not sufficient to mediate binding to the receptor and/or
uptake into the target cells. As shown in Fig. 5, the PMT holotoxin was
less active in the electroporation experiments than in the experiments
using intact cells. This can be explained by a lower activity of the
toxin in the presence of serum, which was also observed in whole-cell
experiments with serum (data not shown). The electroporation
experiments had to be performed in the presence of serum, since the
cells did not reattach to the matrix after electroporation in the
absence of FCS. Alternatively, an additional activation step might
occur during internalization of the toxin, which would result in a
higher activity after uptake of the protein.
Interestingly, a residue in the C-terminal portion of the toxin
(Cys1165) has been found by Ward et al. (22) to be
essential for toxic activity in vivo. However, these studies were
unable to clarify the reason for the functional loss of the mutant.
Here it is shown that this residue is most probably involved in the biological activity of the toxin because the mutant Cys1165Ser of the
fragment PMT581C failed to elicit any toxic affects after electroporation.
In a recent publication on the effects of PMT (24), the N
terminus of the toxin was ascribed a biological activity on
Ca2+-dependent chloride currents in Xenopus
oocytes and an activity on the morphology of Vero cells after
transfection. As reported, N-terminal fragments had no biological
effect in our hands. However, PMT might exhibit a domain structure like
the exoenzyme S of Pseudomonas aeruginosa. This toxin is a
bifunctional protein consisting of separate domains responsible for the
GAP activity on Rho and the ADP-ribosyltransferase activity with Ras as
a target (8).
From the data presented, we propose a domain structure of PMT. We
suggest that the N-terminal part of the toxin contributes to the uptake
of the toxin into the target cell because PMT581C is incapable of
entering cells. The C-terminal part mediates phospholipase C
activation and morphological changes. Cys-1165 within this region is crucial for cellular activity. Interestingly, a similar domain structure was proposed for E. coli CNF1 and CNF2, which have
a 24 to 27% homology with PMT at their N termini. The N terminus of
CNF1 was shown to mediate the uptake into cells (6, 12), while C-terminal fragments exert deamidase activity in vitro and induce
morphological effects after introduction into cells by microinjection
(19).
 |
ACKNOWLEDGMENTS |
The study was financially supported by the Deutsche
Forschungsgemeinschaft and the Fonds der Chemischen Industrie.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Experimentelle und Klinische Pharmakologie und Toxikologie
der Albert-Ludwigs-Universität Freiburg, Hermann-Herder-Str. 5, D-79104 Freiburg, Germany. Phone: 0761-2035301. Fax: 0761-2035311. E-mail: aktories{at}ruf.uni-freiburg.de.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Barth, H.,
F. Hofmann,
C. Olenik,
I. Just, and K. Aktories.
1998.
The N-terminal part of the enzyme component (C2I) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin.
Infect. Immun.
66:1364-1369[Abstract/Free Full Text].
|
| 2.
|
Blank, J. L.,
A. H. Ross, and J. H. Exton.
1991.
Purification and characterization of two G-proteins that activate the beta 1 isozyme of phosphoinositide-specific phospholipase C. Identification as members of the Gq class.
J. Biol. Chem.
266:18206-18216[Abstract/Free Full Text].
|
| 3.
|
Chrisp, C. E., and N. T. Foged.
1991.
Induction of pneumonia in rabbits by use of a purified protein toxin from Pasteurella multocida.
Am. J. Vet. Res.
52:56-61[Medline].
|
| 4.
|
Dudet, L. L.,
P. Chailler,
D. Dubreuil, and B. Martineau-Doize.
1996.
Pasteurella multocida toxin stimulates mitogenesis and cytoskeleton reorganization in swiss 3T3 fibroblasts.
J. Cell. Physiol.
168:173-182[CrossRef][Medline].
|
| 5.
|
Essler, M.,
K. Hermann,
M. Amano,
K. Kaibuchi,
J. Heesemann,
P. C. Weber, and M. Aepfelbacher.
1998.
Pasteurella multocida toxin increases endothelial permeability via rho kinase and myosin light chain phosphatase.
J. Immunol.
161:5640-5646[Abstract/Free Full Text].
|
| 6.
|
Fabbri, A.,
M. Gauthier, and P. Boquet.
1999.
The 5' region of cnf1 harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell-binding domain of the toxin.
Mol. Microbiol.
33:108-118[CrossRef][Medline].
|
| 7.
|
Flatau, G.,
E. Lemichez,
M. Gauthier,
P. Chardin,
S. Paris,
C. Fiorentini, and P. Boquet.
1997.
Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine.
Nature
387:729-733[CrossRef][Medline].
|
| 8.
|
Goehring, U.-M.,
G. Schmidt,
K. J. Pederson,
K. Aktories, and J. T. Barbieri.
1999.
The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases.
J. Biol. Chem.
274:36369-36372[Abstract/Free Full Text].
|
| 9.
|
Higgins, T. E.,
A. C. Murphy,
J. M. Staddon,
A. J. Lax, and E. Rozengurt.
1992.
Pasteurella multocida toxin is a potent inducer of anchorage-independent cell growth.
Proc. Natl. Acad. Sci. USA
89:4240-4244[Abstract/Free Full Text].
|
| 10.
|
Kamp, E. M., and T. G. Kimman.
1988.
Induction of nasal turbinate atrophy in germ-free pigs, using Pasteurella multocida as well as bacterium-free crude and purified dermonecrotic toxin of P. multocida.
Am. J. Vet. Res.
49:1844-1849[Medline].
|
| 11.
|
Lacerda, H. M.,
A. J. Lax, and E. Rozengurt.
1996.
Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells.
J. Biol. Chem.
271:439-445[Abstract/Free Full Text].
|
| 12.
|
Lemichez, E.,
G. Flatau,
M. Bruzzone,
P. Boquet, and M. Gauthier.
1997.
Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains.
Mol. Microbiol.
24:1061-1070[CrossRef][Medline].
|
| 13.
|
Mullan, P. B., and A. J. Lax.
1996.
Pasteurella multocida toxin is a mitogen for bone cells in primary culture.
Infect. Immun.
64:959-965[Abstract].
|
| 14.
|
Murphy, A. C., and E. Rozengurt.
1992.
Pasteurella multocida toxin selectively facilitates phosphatidylinositol 4,5-bisphosphate hydrolysis by bombesin, vasopressin, and endothelin. Requirement for a functional G protein.
J. Biol. Chem.
267:25296-25303[Abstract/Free Full Text].
|
| 15.
|
Pennings, A. M., and P. K. Storm.
1984.
A test in vero cell monolayers for toxin production by strains of Pasteurella multocida isolated from pigs suspected of having atropic rhinitis.
Vet. Microbiol.
9:503-508[CrossRef][Medline].
|
| 16.
|
Rozengurt, E.,
T. Higgins,
N. Chanter,
A. J. Lax, and J. M. Staddon.
1990.
Pasteurella multocida toxin: potent mitogen for cultured fibroblasts.
Proc. Natl. Acad. Sci. USA
87:123-127[Abstract/Free Full Text].
|
| 17.
|
Rutter, J. M., and P. D. Luther.
1984.
Cell culture assay for toxigenic Pasteurella multocida from atrophic rhinitis of pigs.
Vet. Rec.
114:393-396[Abstract].
|
| 18.
|
Schmidt, G.,
P. Sehr,
M. Wilm,
J. Selzer,
M. Mann, and K. Aktories.
1997.
Gln63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor 1.
Nature
387:725-729[CrossRef][Medline].
|
| 19.
|
Schmidt, G.,
J. Selzer,
M. Lerm, and K. Aktories.
1998.
The Rho-deamidating cytotoxic-necrotizing factor CNF1 from Escherichia coli possesses transglutaminase activity cysteine-866 and histidine-881 are essential for enzyme activity.
J. Biol. Chem.
273:13669-13674[Abstract/Free Full Text].
|
| 20.
|
Seo, B.,
E. W. Choy,
W. E. Maudsley,
W. E. Miller,
B. A. Wilson, and L. M. Luttrell.
2000.
Pasteurella multocida toxin stimulates mitogen-activated protein kinase via Gq/11-dependent transactivation of the epidermal growth factor receptor.
J. Biol. Chem.
275:2239-2245[Abstract/Free Full Text].
|
| 21.
|
Staddon, J. M.,
C. J. Barker,
A. C. Murphy,
N. Chanter,
A. J. Lax,
R. H. Michell, and E. Rozengurt.
1991.
Pasteurella multocida toxin, a potent mitogen, increases inositol 1,4,5-triphosphate and mobilizes Ca2+ in Swiss 3T3 cells.
J. Biol. Chem.
266:4840-4847[Abstract/Free Full Text].
|
| 22.
|
Ward, P. N.,
A. J. Miles,
I. G. Sumner,
L. H. Thomas, and A. J. Lax.
1998.
Activity of the mitogenic Pasteurella multocida toxin requires an essential C-terminal residue.
Infect. Immun.
66:5636-5642[Abstract/Free Full Text].
|
| 23.
|
Wilson, B. A.,
L. R. Aminova,
V. G. Ponferrada, and M. Ho.
2000.
Differential modulation and subsequent blockade of mitogenic signaling and cell cycle progression by Pasteurella multocida toxin.
Infect. Immun.
68:4531-4538[Abstract/Free Full Text].
|
| 24.
|
Wilson, B. A.,
V. G. Ponferrada,
J. E. Vallance, and M. F. Ho.
1999.
Localization of the intracellular activity domain of Pasteurella multocida toxin to the N terminus.
Infect. Immun.
67:80-87[Abstract/Free Full Text].
|
| 25.
|
Wilson, B. A.,
X. Zhu,
M. Ho, and L. Lu.
1997.
Pasteurella multocida toxin activates the inositol triphosphate signaling pathway in Xenopus oocytes via Gq -coupled phospholipase C- 1.
J. Biol. Chem.
272:1268-1275[Abstract/Free Full Text].
|
Infection and Immunity, June 2001, p. 3628-3634, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3628-3634.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Orth, J. H. C., Fester, I., Preuss, I., Agnoletto, L., Wilson, B. A., Aktories, K.
(2008). Activation of G{alpha}i and Subsequent Uncoupling of Receptor-G{alpha}i Signaling by Pasteurella multocida Toxin. J. Biol. Chem.
283: 23288-23294
[Abstract]
[Full Text]
-
Aminova, L. R., Luo, S., Bannai, Y., Ho, M., Wilson, B. A.
(2008). The C3 domain of Pasteurella multocida toxin is the minimal domain responsible for activation of Gq-dependent calcium and mitogenic signaling. Protein Sci.
17: 945-949
[Abstract]
[Full Text]
-
Belyi, Y., Tabakova, I., Stahl, M., Aktories, K.
(2008). Lgt: a Family of Cytotoxic Glucosyltransferases Produced by Legionella pneumophila. J. Bacteriol.
190: 3026-3035
[Abstract]
[Full Text]
-
Satchell, K. J. F.
(2007). MARTX, Multifunctional Autoprocessing Repeats-in-Toxin Toxins. Infect. Immun.
75: 5079-5084
[Full Text]
-
Kitadokoro, K., Kamitani, S., Miyazawa, M., Hanajima-Ozawa, M., Fukui, A., Miyake, M., Horiguchi, Y.
(2007). Crystal structures reveal a thiol protease-like catalytic triad in the C-terminal region of Pasteurella multocida toxin. Proc. Natl. Acad. Sci. USA
104: 5139-5144
[Abstract]
[Full Text]
-
Orth, J. H. C., Aktories, K., Kubatzky, K. F.
(2007). Modulation of Host Cell Gene Expression through Activation of STAT Transcription Factors by Pasteurella multocida Toxin. J. Biol. Chem.
282: 3050-3057
[Abstract]
[Full Text]
-
Belyi, Y., Niggeweg, R., Opitz, B., Vogelsgesang, M., Hippenstiel, S., Wilm, M., Aktories, K.
(2006). Legionella pneumophila glucosyltransferase inhibits host elongation factor 1A. Proc. Natl. Acad. Sci. USA
103: 16953-16958
[Abstract]
[Full Text]
-
Orth, J. H. C., Lang, S., Taniguchi, M., Aktories, K.
(2005). Pasteurella multocida Toxin-induced Activation of RhoA Is Mediated via Two Families of G{alpha} Proteins, G{alpha}q and G{alpha}12/13. J. Biol. Chem.
280: 36701-36707
[Abstract]
[Full Text]
-
Orth, J. H. C., Lang, S., Aktories, K.
(2004). Action of Pasteurella multocida Toxin Depends on the Helical Domain of G{alpha}q. J. Biol. Chem.
279: 34150-34155
[Abstract]
[Full Text]
-
Shime, H., Ohnishi, T., Nagao, K., Oka, K., Takao, T., Horiguchi, Y.
(2002). Association of Pasteurella multocida Toxin with Vimentin. Infect. Immun.
70: 6460-6463
[Abstract]
[Full Text]
-
Pullinger, G. D., Sowdhamini, R., Lax, A. J.
(2001). Localization of Functional Domains of the Mitogenic Toxin of Pasteurella multocida. Infect. Immun.
69: 7839-7850
[Abstract]
[Full Text]